Aspirational Valeant makes $500m acquisition, eyes 'Top 5' spot
This article was originally published in Scrip
Executive Summary
Valeant Pharmaceuticals is to acquire PreCision Dermatology for $475m in cash, plus an additional $25m if sales-based milestones are achieved. J Michael Pearson, CEO of Canada's largest public pharma company, announced a new "strategic initiative" last month, to become "one of the top-five most valuable pharmaceutical companies by the end of 2016."
You may also be interested in...
Finance Watch: A Bountiful November Harvest For Venture-Backed Biopharma
Five funds raised more than $1bn to back biotech firms; Arcus leads recent VC rounds with $107m GV-backed Series C; Celgene, Valeant sell notes to retire debt; and Alnylam cashes in on investor goodwill.
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.